ITM-11 Shows Superior GEP-NET Response in Phase 3 Trial
Progression-free survival reached 23.9 months with 177Lu-edotreotide versus 14.1 months on everolimus in the Phase 3 COMPETE trial (HR...
eClinical Tech News
Acrivon Highlights AP3 Platform, ACR-2316 Preclinical Data
Acrivon reported early clinical activity for its dual WEE1/PKMYT1 inhibitor ACR-2316, including a confirmed partial response during Phase 1...
Eleva Advances C3G Drug CPV-104 into Phase 1b Trial
Eleva completed the single-ascending dose portion of its first-in-human study of CPV-104, a recombinant human Factor H, in 21...
Ogsiveo Trial Shows Long-Term Efficacy for Desmoid Tumors
Objective response on nirogacestat improved from 34.3% at year one to 45.7% with continuous treatment for up to four...
PIVOT-PO Data: A New Hope for Oral cUTI Antibiotic Needs
Non-inferiority was achieved in the pivotal Phase 3 PIVOT-PO trial of oral tebipenem HBr for complicated urinary tract infections,...
Adarx Presents Kidney Disease Data at ASN Kidney Week 2025
ADARx will present interim Phase 1 data for ADX-038, an siRNA targeting complement factor B, at ASN Kidney Week...
Avance Clinical Launches Center to Accelerate Biotech Trials
Avance Clinical has launched an Early Phase Center of Excellence for Biotechs, bundling scientific and regulatory guidance with operational...
Promising Results for CRB-701 in HNSCC & Cervical Cancers
At the 3.6 mg/kg dose of CRB-701, objective response rates reached 47.6% in head and neck squamous cell carcinoma,...
Olema Oncology Data on Palazestrant Combo for Breast Cancer
In a Phase 1b/2 study of palazestrant plus ribociclib in ER+/HER2- advanced or metastatic breast cancer, the 120 mg...
CRB-701: Remarkable Clinical Responses in HNSCC Cancers
At the 3.6 mg/kg dose of CRB-701, Corbus reported objective response rates of 47.6% in head and neck squamous...